Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 738

1.

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.

Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N.

Cancers (Basel). 2019 Jul 31;11(8). pii: E1084. doi: 10.3390/cancers11081084.

2.

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.

Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW.

Br J Cancer. 2019 Jul 30. doi: 10.1038/s41416-019-0534-2. [Epub ahead of print]

PMID:
31363170
3.

Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC Guidelines) a 2019 update.

Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y.

Hepatol Res. 2019 Jul 23. doi: 10.1111/hepr.13411. [Epub ahead of print]

PMID:
31336394
4.

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Oncology. 2019 Jul 15:1-9. doi: 10.1159/000501281. [Epub ahead of print]

PMID:
31307035
5.

Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability.

Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.

Hepatol Res. 2019 Jul 13. doi: 10.1111/hepr.13407. [Epub ahead of print]

PMID:
31301213
6.

Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells.

Kamata K, Watanabe T, Minaga K, Hara A, Yoshikawa T, Okamoto A, Yamao K, Takenaka M, Park AM, Kudo M.

Int Immunol. 2019 Jul 9. pii: dxz050. doi: 10.1093/intimm/dxz050. [Epub ahead of print] No abstract available.

PMID:
31287532
7.

Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.

Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M.

Cancers (Basel). 2019 Jul 7;11(7). pii: E952. doi: 10.3390/cancers11070952.

8.

Large balloon expansion method for re-intervention after endoscopic ultrasound-guided hepaticogastrostomy for stent obstruction.

Takenaka M, Nakai A, Kudo M.

Dig Endosc. 2019 Jul 5. doi: 10.1111/den.13462. [Epub ahead of print] No abstract available.

PMID:
31273839
9.

Conversion of percutaneous transhepatic gallbladder drainage to endoscopic ultrasound-guided hepaticogastrostomy by the intentional expansion method.

Takenaka M, Kamata K, Kudo M.

Dig Endosc. 2019 Jul 4. doi: 10.1111/den.13479. [Epub ahead of print]

PMID:
31271677
10.

Novel concept using a plastic stent for endoscopic ultrasound-guided hepaticogastrostomy adjusting the length according to the patient's anatomy.

Takenaka M, Minaga K, Yoshikawa T, Okamoto A, Nakai A, Omoto S, Kudo M.

Endoscopy. 2019 Jul 1. doi: 10.1055/a-0948-3630. [Epub ahead of print] No abstract available.

PMID:
31261432
11.

Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.

Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW.

Br J Cancer. 2019 Jul;121(3):218-221. doi: 10.1038/s41416-019-0506-6. Epub 2019 Jun 28. Erratum in: Br J Cancer. 2019 Jul 30;:.

PMID:
31249394
12.

Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version).

Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N.

Hepatol Res. 2019 Jun 24. doi: 10.1111/hepr.13394. [Epub ahead of print]

PMID:
31231916
13.

Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.

Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Komeda Y, Kudo M.

J Med Virol. 2019 Oct;91(10):1804-1810. doi: 10.1002/jmv.25515. Epub 2019 Jul 2.

PMID:
31199513
14.

Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

Kudo M.

Liver Cancer. 2019 May;8(3):143-154. doi: 10.1159/000500143. Epub 2019 Apr 29. No abstract available.

15.

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.

Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Cruz CD, Kudo M.

J Hepatol. 2019 Jun 7. pii: S0168-8278(19)30300-9. doi: 10.1016/j.jhep.2019.05.014. [Epub ahead of print]

16.

Autoimmune hepatitis and IgG4-related disease.

Minaga K, Watanabe T, Chung H, Kudo M.

World J Gastroenterol. 2019 May 21;25(19):2308-2314. doi: 10.3748/wjg.v25.i19.2308. Review.

17.

RICK/RIP2 is a NOD2-independent nodal point of gut inflammation.

Watanabe T, Minaga K, Kamata K, Sakurai T, Komeda Y, Nagai T, Kitani A, Tajima M, Fuss IJ, Kudo M, Strober W.

Int Immunol. 2019 May 27. pii: dxz045. doi: 10.1093/intimm/dxz045. [Epub ahead of print]

PMID:
31132297
18.

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Cancer Med. 2019 Jul;8(8):3719-3728. doi: 10.1002/cam4.2241. Epub 2019 May 24.

19.

Cabozantinib for advanced hepatocellular carcinoma.

Kudo M.

Hepatobiliary Surg Nutr. 2019 Apr;8(2):153-156. doi: 10.21037/hbsn.2018.11.22. No abstract available.

20.

A novel technique for stent dysfunction after endoscopic ultrasound-guided hepaticogastrostomy with antegrade stenting.

Okamoto A, Minaga K, Takenaka M, Yoshikawa T, Kamata K, Yamao K, Kudo M.

Endoscopy. 2019 May 9. doi: 10.1055/a-0890-3220. [Epub ahead of print] No abstract available.

PMID:
31071750

Supplemental Content

Loading ...
Support Center